

Prospects for mTOR Inhibitor Use in Patients with Polycystic Kidney Disease and Hamartomatous Diseases

Vicente E. Torres,* Alessandra Boletta,[†] Arlene Chapman,[‡] Vincent Gattone,[§] York Pei,^{||} Qi Qian,* Darren P. Wallace,[¶] Thomas Weimbs,** and Rudolf P. Wüthrich^{††}

*Division of Nephrology, Mayo Clinic College of Medicine, Rochester, Minnesota; [†]Dulbecco Telethon Institute at DIBIT, San Raffaele Scientific Institute, Milan, Italy; [‡]Emory University School of Medicine, Atlanta, Georgia; [§]Department of Anatomy, Indiana University School of Medicine, Indianapolis, Indiana; ^{||}Toronto General Hospital, Toronto, Ontario, Canada; [¶]Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas; **Department of Molecular, Cellular, and Developmental Biology, University of California Santa Barbara, Santa Barbara, California; and ^{††}Division of Nephrology, University Hospital Zurich, Zurich, Switzerland

Mammalian target of rapamycin (mTOR) is the core component of two complexes, mTORC1 and mTORC2. mTORC1 is inhibited by rapamycin and analogues. mTORC2 is impeded only in some cell types by prolonged exposure to these compounds. mTOR activation is linked to tubular cell proliferation in animal models and human autosomal dominant polycystic kidney disease (ADPKD). mTOR inhibitors impede cell proliferation and cyst growth in polycystic kidney disease (PKD) models. After renal transplantation, two small retrospective studies suggested that mTOR was more effective than calcineurin inhibitor-based immunosuppression in limiting kidney and/or liver enlargement. By inhibiting vascular remodeling, angiogenesis, and fibrogenesis, mTOR inhibitors may attenuate nephroangiosclerosis, cyst growth, and interstitial fibrosis. Thus, they may benefit ADPKD at multiple levels. However, mTOR inhibition is not without risks and side effects, mostly dose-dependent. Under certain conditions, mTOR inhibition interferes with adaptive increases in renal proliferation necessary for recovery from injury. They restrict Akt activation, nitric oxide synthesis, and endothelial cell survival (downstream from mTORC2) and potentially increase the risk for glomerular and peritubular capillary loss, vasospasm, and hypertension. They impair podocyte integrity pathways and may predispose to glomerular injury. Administration of mTOR inhibitors is discontinued because of side effects in up to 40% of transplant recipients. Currently, treatment with mTOR inhibitors should not be recommended to treat ADPKD. Results of ongoing studies must be awaited and patients informed accordingly. If effective, lower dosages than those used to prevent rejection would minimize side effects. Combination therapy with other effective drugs could improve tolerability and results.

Clin J Am Soc Nephrol 5: 1312–1329, 2010. doi: 10.2215/CJN.01360210

Careful clinical observations have been key to the identification of the genes mutated in autosomal dominant polycystic kidney disease (ADPKD) and tuberous sclerosis complex (TSC), the function of the gene products, and mammalian target of rapamycin (mTOR) signaling as an important player in the pathogenesis of ADPKD and hamartomatous diseases. ADPKD, a potentially lethal monogenic disorder with an estimated prevalence of 1:400 to 1:1000, is characterized by the development of cysts in the kidneys, liver, seminal vesicles, pancreas, and arachnoid membrane; intracranial aneurysms and dolichoectasias; aortic root dilation and aneurysms; mitral valve prolapse; and abdominal wall hernias (1). TSC, an autosomal dominant disease with a prevalence of 1:6000 to 1:10,000, is characterized by multiple brain, retina, skin, kidney, heart, and lung hamartomas (2). A Portuguese family segregating a chromosome

16:22 translocation with ADPKD and TSC helped to identify the *TSC2* and *PKD1* genes immediately adjacent to each other on chromosome 16 (3,4). The cloning of *PKD1* and subsequently *PKD2*, genes that encode polycystin-1 and polycystin-2, led to the identification of a new subfamily of transient receptor potential channels (5). The cloning of *TSC1* and *TSC2*, genes that encode hamartin and tuberlin, made possible studies of *Tsc1* and *Tsc2* homologues in *Drosophila* and the subsequent identification of the hamartin-tuberlin heterodimer as a GTPase-activating protein for Rheb (Ras homolog enriched in brain), linking growth factor, nutrient, and energy sensing signals to mTOR and mTOR-dependent targets (6). The description of a contiguous gene syndrome characterized by early onset of severe polycystic kidney disease (PKD) in patients with deletions involving *PKD1* and *TSC2* suggested that polycystin-1 and tuberlin function in a common pathway (7). A better understanding of the molecular mechanisms laid out the foundation for the development of potentially effective therapies (8). The purpose of this review is to critically analyze the potential benefits and risks of mTOR inhibitors to treat ADPKD, TSC, and other hamartomatous diseases.

Published online ahead of print. Publication date available at www.cjasn.org.

Correspondence: Dr. Vicente E. Torres, Division of Nephrology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, Minnesota 55905. Phone: 507-284-7527; Fax: 507-266-9315; E-mail: torres.vicente@mayo.edu

Overview of mTOR Signaling and Inhibitors

mTOR is a serine/threonine kinase of the phosphoinositide 3-kinase (PI3K)-related kinase family identified as the mammalian target of rapamycin (sirolimus). Rapamycin is a fungal metabolite found to have potent growth-inhibitory and immunosuppressant properties (9,10).

mTOR is the core component of two distinct complexes only partially characterized: complex 1 (mTORC1) and complex 2 (mTORC2) (9). In addition to mTOR, both complexes contain the small adaptor G β L but differ in the composition of additional adaptors. In particular, the presence of the Rictor protein in the complex characterizes mTORC2, whereas the Raptor protein defines mTORC1 (Figure 1, A and B) (10–12). mTOR can be specifically inhibited by rapamycin only when it is in mTORC1, leading to the initial definition of mTORC1 as “rapamycin sensitive” and of mTORC2 as “rapamycin insensitive” (12), although subsequent studies demonstrated that the mTORC2 assembly can be inhibited in long-term treatments with rapamycin in some cell types (13).

The functions and downstream biologic effects of the two complexes are also different. mTORC1 is involved in regulating cell cycle progression, translational control, and cellular energy responses (11), whereas mTORC2 has been recently identified as the kinase responsible for phosphorylating Akt (or protein kinase B) in Ser-473 and plays a role in regulating the actin cytoskeleton (12,14).

mTORC1 is activated in response to an elevated GTP-bound form of Rheb, a small GTPase of the Ras superfamily, through an unclear mechanism (15). The guanine nucleotide exchange

factor inducing Rheb’s active state was recently identified in *Drosophila* (16), whereas the GTPase-activating protein (GAP) inducing its inactive state is tuberlin, the *TSC2* gene product (17). The mechanisms regulating the complex *TSC1/TSC2* have been the focus of intense investigations, leading to the identification of several cascades that regulate the GAP activity of *TSC2*, and consequently Rheb/mTORC1 (Figure 2). Tuberlin can be phosphorylated in numerous phosphosites (18). Several kinases have been reported to phosphorylate tuberlin; some of them lead to inhibition of its GAP activity, ultimately resulting in upregulation of mTORC1, including Akt (19), p90RSK (20), and the extracellular-related kinases (ERKs) (21), whereas others lead to enhanced GAP activity, ultimately resulting in downregulation of mTORC1, including 5’-AMP-activated protein kinase (AMPK) (22), GSK3 β (23), and the hypoxia-induced molecule REDD1 (24).

The two effectors of mTORC1 that are better characterized are the ribosomal S6 kinases (SK6; p70S6K1 and p70S6K2) and the eukaryotic initiation factor 4 binding proteins 1 and 2 (4E-BP1 and 4E-BP2) (9,10). S6K is activated by phosphorylation at several sites, but the one with highest sensitivity to rapamycin and thus believed to be a direct target of mTORC1 is threonine 389 (25). Upon activation, S6K phosphorylates subunit 6 of ribosomal protein, leading to a general activation of translation through an unclear and still highly debated mechanism (9,10). Phosphorylation of 4E-BP instead leads to dissociation from eukaryotic initiation factor 4E, which is released, allowing the formation of translation initiation complexes (9,10). Thus, both branches of the downstream effectors




Figure 1. Schematic overview of the mTOR complexes, mTORC1 and mTORC2, and of the feedback loop. (A) The rapamycin-sensitive mTORC1 comprises, in addition to the mTOR kinase, raptor, G β L, PRAS40, and DEPTOR. (B) mTORC2 contains Rictor, G β L, Protor, Sin, and DEPTOR. (C) mTORC1 regulates translation, cell size, and the cell cycle, as well as autophagy and cellular metabolism. mTORC2 regulates the cellular cytoskeleton. In addition, mTORC2 is the kinase responsible for phosphorylation of Akt in Ser473. Activation of mTORC1 results in regulation of a negative feedback loop through which S6K inhibits the insulin receptor signaling by phosphorylating and inducing degradation of the adaptor IRS. As a consequence, activation of mTORC1 downregulates PI3k/Akt and the ERKs, whereas inhibition of mTORC1 upregulates both cascades.




Figure 2. Overview of the cascades converging on regulation of the TSC2 gene product tuberin. Downstream of the tyrosine kinase receptor (TKR) signaling, Akt, ERK, and p90RSK can all phosphorylate different residues of TSC2, resulting in inhibition of its GAP activity toward Rheb (right diagram). As a result, activation of TKRs results in activation of the mTORC1 cascade. Amino acids can also activate mTORC1 downstream of the TSC1/TSC2 complex by acting directly on mTORC1. In contrast, REDD1, AMPK, and GSK3 β act as energy or hypoxia sensors and are able to potently inhibit the mTORC1 cascade by enhancing the TSC1/TSC2 activity toward Rheb (left diagram). Wnts can activate the mTORC1 complex by inhibiting GSK3 β .

of mTORC1 regulate translation and growth (size) of cells (Figure 1C).

In addition to acting on subunit 6 of ribosomal protein, S6K was recently found to regulate a feedback loop toward the PDGF receptor and the insulin receptor substrate (IRS) (26,27). Upon phosphorylation in Ser/Thr, IRS undergoes degradation (28), thus attenuating the response to insulin and the activation of PI3K/Akt and Ras/ERKs (29,30). As a result of this effect, a feedback loop is initiated whereby activation of mTORC1 results in activation of S6K, which in turn downregulates the IRS, PI3K/Akt, and Ras/ERKs, thus diminishing their effect on the TSC1/TSC2 complex and ultimately restoring the basal activity of mTORC1. Because of these feedback loops, constitutive inhibition of mTORC1 ultimately results in upregulation of PI3K/Akt and Ras/ERK pathways (29,30). It is important to consider this when designing therapeutic approaches through the inhibition of mTORC1.

As outlined above, mTOR was identified as the target of rapamycin and subsequently shown to be specifically inhibited by this metabolite. Rapamycin and its subsequent derivatives CCI-779 (temsirolimus), RAD001 (everolimus), and AP23573 (deforolimus) all share a similar chemical structure and comprise a binding site for the intracellular immunophilin FKBP12 (31). Interaction with FKBP12 is an absolute requirement for rapamycin and its derivatives to bind to and inhibit mTOR (31). Whereas the mechanism of action for all of these drugs is similar, the different chemical composition renders the rapamycin derivatives soluble in water, allowing for intravenous or oral administration (31). All of these molecules are specific for inhibition of mTOR only when it is associated with mTORC1.

In certain cases, this might represent a problem, because inhibition of mTORC1 leads to upregulation of tumorigenic cascades (e.g., PI3K/Akt and Ras/ERKs) as highlighted above. Although long-term treatment with rapamycin was reported to downregulate mTORC2, this effect appears to be cell-type-dependent (13). Therefore, treatment with rapamycin will be effective and safe mostly in tissues (cancers or cystic tissues) in which mTORC2 is inhibited in long-term treatments. A new generation of drugs directed against the mTOR catalytic site is being developed that might be effective on mTORC1 and mTORC2 (32). These drugs will be preferable in cases where the feedback loops are insensitive to long-term treatment with rapamycin. Alternatively, combination therapies might be used to bypass this problem (33,34).

Dysregulation of mTOR Signaling in Hamartoma Syndromes

Hamartomas are a benign, histologically defined subtype of tumors with relatively normal differentiation but disorganized tissue architecture. Hamartomas can present as incidental findings in the general population or clinically defined familial syndromes with variable expressivity involving one or more body sites. Positional cloning of Mendelian hamartoma syndromes has identified at least seven disease genes (*TSC1*, *TSC2*, *PTEN*, *STK11*, *FLCN*, *PKD1*, and *NF1*) that encode components of multiple signaling pathways that converge at the mTORC1 complex (Figure 3, Table 1). Although an autosomal dominant inheritance underlies all of these syndromes, a “2-hit” cellular recessive mechanism has been shown in many but not all of the




Figure 3. Multiple signaling (AMPK, Ras/ERK, PIK3) pathways converge at the TSC1-TSC2 complex to regulate the rapamycin-sensitive mTORC1 activity, protein synthesis, and cell growth. Mutations of at least seven (blue) disease genes associated with Mendelian hamartoma syndromes have been linked to mTORC1 activation (see text for more details), providing a rationale for the potential therapeutic use of mTOR inhibitors in these disorders. 4EBP1, initiation factor 4E binding protein; FNIP1, folliculin-interacting protein 1; NF1, neurofibromin 1; PTEN, phosphatase and tensin homolog; RSK, p90 S6K 1; STK11, serine/threonine kinase 11 (also known as LKB1); TSC1, hamartin; TSC2, tuberlin.

associated hamartomas, suggesting that the disease genes function as tumor suppressors (35,36). Interestingly, some but not all of these mTOR-dysregulated hamartoma syndromes are associated with an increased risk of cancer (35,37,38).

Figure 3 shows the components of the key signaling pathways that converge at the rapamycin-sensitive mTORC1 and how disease mutations affecting some of the upstream regulatory proteins can lead to mTOR activation. In this regard, the most extensively characterized example is TSC (35,39). The TSC1-TSC2 protein complex serves as a node that integrates cues from growth factors, nutrients, and other external signals to regulate mTORC1 activity. Loss-of-function TSC1 or TSC2 mutations are associated with increased Rheb-GTP levels and aberrant activation of mTORC1 in various TSC-associated hamartomas (39,40). Growth factor stimulation and increased Akt activity, after receptor tyrosine kinase activation, provide a major upstream negative regulatory signal to TSC2. Loss-of-function mutations of phosphatase and tensin homolog, a lipid phosphatase that negatively regulates Akt, have been documented in several closely related clinical syndromes linked to aberrant mTOR activation (41,42). Similarly, growth factors that lead to RAS activation can also provide an upstream negative regulatory signal to TSC2 through the mitogen-activated protein kinase (ERK/RSK) cascade. Loss-of-function mutations of neurofibromin, which negatively regulates RAS, can cause aberrant mTOR activation in neurofibromatosis (43). By contrast, cellular energy depletion (low AMP) is sensed by AMPK and

Table 1. Familial hamartoma syndromes linked to mTOR dysregulation (39–48)

Gene	Protein	Protein Function	Disease	Clinical Features
TSC1	Hamartin (TSC1)	Binding partner for TSC2	Tuberous sclerosis	Hamartomas in skin, central nervous system, and heart; renal cysts and angiomyolipomas; lymphangiomyomatosis
TSC2	Tuberlin (TSC2)	Rheb GAP	Tuberous sclerosis	Same as above
PTEN	PTEN	3'-phosphoinositide phosphatase	PTEN-hamartoma tumor syndromes	Hamartomas in multiple organs, lentiginos, macrocephaly, hemihypertrophy, increased risk of breast and thyroid cancer
STK11	STK11	AMPK-dependent regulator of TSC2	Peutz-Jeghers syndrome	Hamartomas in GI tract, lentiginos, increased risk of GI and non-GI carcinomas
FLCN	Folliculin (FLCN)	AMPK-dependent regulator of TSC2	BHD syndrome	Hamartomas in multiple organs (including hair follicles), lung cysts (spontaneous pneumothorax), increased risk of renal carcinomas
PKD1	Polycystin 1 (PC1)	Regulator of TSC2?	Autosomal dominant polycystic kidney disease	Renal and extrarenal cysts, cardiac valvular and vascular defects (including intracranial arterial aneurysms), hernias, colonic diverticulosis
NF1	Neurofibromin 1 (NF1)	RAS GAP	Neurofibromatosis	Neurocutaneous hamartomas, endocrine tumors, increased risk of malignant peripheral nerve tumors, sarcomas, myeloid leukemia

GI, gastrointestinal; PTEN, phosphatase and tensin homolog (PTEN-hamartoma tumor syndromes include Cowden disease, Bannayan-Riley-Ruvalcaba syndrome, Proteus syndrome, and Lhermitte-Duclos syndrome); STK11, serine/threonine kinase 11 (also known as LKB1).

provides a positive regulatory signal to TSC2. Loss-of-function mutations of STK11 (LKB1), which release TSC2 activation by AMPK, cause Peutz–Jeghers syndrome and aberrant mTOR activation (44). Likewise, through a complex, incompletely understood interaction between folliculin (FLCN), FLCN-interacting protein 1, and AMPK, loss-of-function mutations of FLCN, the product of a gene that is mutated in Birt-Hogg-Dubé (BHD) syndrome, have also been shown to cause aberrant mTOR activation (45,46). More recently, aberrant mTOR activation has been implicated in playing a pathogenic role in ADPKD (see later section) (47).

The documentation of aberrant mTOR activation in the above hamartoma syndromes provides a strong rationale for testing the therapeutic efficacy of mTOR inhibitors in these disorders. Indeed, a recently completed nonrandomized, open-label study of 20 patients with TSC showed that a 12-month treatment with rapamycin reduced the mean volume of renal angiomyolipomas by approximately 50% compared with the baseline value and improved the lung function of 14 of the same patients who also have lymphangioleiomyomatosis. However, the renal and pulmonary treatment benefits tended to reverse in most patients after discontinuation of rapamycin for 1 year (48). Despite these exciting initiatives, a better understanding of the pathobiology of mTOR signaling in the above hamartoma syndromes is needed if the therapeutic potential of mTOR inhibitors in these disorders is to be fully exploited. For example, what are the molecular bases for the distinct phenotypic differences and tissue specificities in these disorders? Does mTORC2 play a role in their pathobiology (37)? Is ciliary dysfunction involved in their pathogenesis (38)? Why is there an increased risk for cancer in some but not all of these disorders (Table 1)? Several groups have begun to address this latter question by suggesting that hyperactive mTOR signaling activates crucial negative feedback mechanisms through S6K (Figure 3) (27,49) or PDGF receptor-mediated (26) downregulation of IRS, PI3K, and Akt activities. This may explain why the risk of cancer is not increased in ADPKD, but is increased in phosphatase and tensin homolog-associated hamartoma syndromes. However, this negative feedback mechanism should also operate in neurofibromatosis, Peutz–Jeghers, and BHD syndromes, all of which are associated with an increased risk of cancer (43,44,46).

mTOR Signaling in PKD

The earliest suggestion for a role of mTOR in PKD came from the observation that many TSC patients develop renal cysts. The *PKD1* and *TSC2* genes were found to lie immediately adjacent to each other on chromosome 16 (3,50) in a tail-to-tail orientation, and this gene proximity is highly conserved from humans to fish (51), suggesting that the gene products may be functionally linked or that their expression may at least be coregulated. In approximately 2% to 3% of TSC patients, a contiguous germline deletion that affects *TSC2* and *PKD1* leads to much earlier onset and more severe PKD than mutations in the individual genes (7). Thus, the gene products may function in a common pathway, and the severe cystic phenotype in patients with a combined *TSC2* and *PKD1* mutation may be due

to gene dosage that affects two components of the same pathway.

Components of the mTOR pathway (mTOR, S6K, and S6) were found to be aberrantly phosphorylated in epithelial cells of a subset of renal cysts in human ADPKD, autosomal recessive PKD, and PKD mouse models (38,47,52,53). The observation that some but not all of the cysts exhibit signs of mTOR activation suggests that this pathway may only be active during certain stages of cyst development or that other signaling pathways may be required for full mTOR activation. It is currently unclear if mTOR activation is sufficient to induce cyst formation because renal cysts are observed in only 32% of TSC patients and in most cases the cystic disease is relatively mild (54). These observations suggest that mTOR activation may be important, but not sufficient, for cyst growth. However, several groups independently found that rapamycin reduced renal cyst growth in rodent models of PKD (see below).

The mechanism for mTOR activation in ADPKD must ultimately be due to a direct or indirect mechanistic link to the polycystins. The identification of a binding interaction between the cytoplasmic tail of PC1 and tuberlin (47) supports a model in which PC1 normally suppresses mTOR activity by its interaction with tuberlin (47,55,56). Recently, *Pkd1*^{-/-} mouse embryonic fibroblasts were shown to have increased cell size and phosphorylation levels of S6K, S6, and 4EBP1, consistent with activation of mTORC1 (57). Conversely, PC1 overexpression reduced ERK activation and S6KThr389, S6, and 4EBP1 phosphorylation, despite strong Akt activation. Additional studies using MDCK cells expressing dominant negative or constitutively active Akt or MEK constructs confirmed that PC1 downregulates cell size and mTORC1 activation by affecting the ERK-mediated phosphorylation of tuberlin at S664. Clinical studies have demonstrated high levels of constitutively active ERK in TSC-associated lesions that lack loss of heterozygosity in the TSC genes and in *TSC2*^{+/-} cell lines (58), which suggests a positive feedback loop, with ERK activation not only upstream but also downstream of TSC/mTOR.

Currently, the role of Akt in mTOR regulation and cell proliferation in PKD remains unclear. In normal renal cells, Akt phosphorylates an inhibitory site on B-Raf, preventing cAMP activation of the B-Raf/MEK/ERK signaling pathway and cell proliferation (59–61). In cultured cells from human ADPKD cysts, Akt activity is reduced, and cAMP activates B-Raf signaling to the MEK/ERK pathway and cell proliferation (60). On the other hand, phosphorylated Akt (p-Akt) was found to be elevated in mitotic cells in *Cy/+* kidneys (62). The reason for the discrepancy in basal Akt activity between cultured human ADPKD cells and cyst cells of *Cy/+* kidneys *in vivo* is unclear. It is possible that Akt may modulate mTORC1 activity independent of its inhibitory effect on B-Raf.

mTOR is active in renal epithelial cells in developing, postnatal kidneys of mice, but markers such as P-mTOR and P-S6 become almost undetectable in adult kidneys (46) (Shillingford and Weimbs, unpublished results). This, and the finding that high-level rapamycin treatment had no apparent structural or functional effects on the healthy, adult mouse or rat kidney (47,63,64), suggests that mTOR activity is not needed for nor-

mal renal function. By contrast, increased cell proliferation, fibrosis, and cellular hypertrophy after renal injury (e.g., ischemia/reperfusion and ureteral obstruction) and during compensatory hypertrophy after unilateral nephrectomy are largely inhibited by rapamycin treatment (64–67). These studies suggest that activation of the mTOR pathway is an essential, but normally dormant, component of the response to renal injury (64–67). It has been suggested that the changes leading to renal cyst growth in PKD represent the aberrant activation of a renal repair pathway (55,56). Given that the PKD rodent models that exhibit activated mTOR and/or respond to mTOR inhibition involve a wide variety of affected proteins (Table 2), it has been suggested that all of these proteins (and likely many more) function in pathways that eventually converge on the mTOR pathway (55,56). Such a convergent pathway represents a highly attractive therapeutic target.

Efficacy of mTOR Inhibitors in PKD Rodent Models

In all PKD rodent models tested so far, treatment with mTOR inhibitors has proven effective in inhibiting cyst growth and kidney enlargement and preserving renal function (Table 2). In the Cy/+ rat, a mutation in *Anks6* (formally *Pkdr1*) that encodes for SamCystin, a novel protein with no known function, causes slowly progressive cystic disease (68). Administration of 0.2 mg/kg per d rapamycin by intraperitoneal injection for 5 weeks (69), or 2 mg/kg per d orally for 8 to 12 weeks (70,71), reduced PKD progression and preserved renal function (69,70). Everolimus, a rapamycin analogue, proved equally effective in the Cy/+ rat (72). Long-term rapamycin treatment from 1 to 12 months resulted in a normalization of kidney volume, renal function, blood pressure, and heart weight (73).

The *orpk*-rescue mouse arose from alterations of the gene encoding for Polaris, a protein involved in ciliogenesis and intraflagellar transport, leading to slowly progressing PKD (74). Treatment with rapamycin for 1 month (5 mg/kg per d, intraperitoneally) resulted not only in inhibition of renal growth but significant regression of already enlarged kidneys, as determined by magnetic resonance imaging (47). This was likely due to the observed induction of apoptosis, specifically in cyst-lining cells. In the same study, the effect of rapamycin was tested in the *bpk* mouse, a rapidly progressive PKD model caused by a mutation in bicaudal-C, an RNA-binding protein of no known function in mammals. Rapamycin treatment for 2 weeks (1.67 or 5 mg/kg per d, intraperitoneally) was highly effective in slowing renal and cyst growth and preserving renal function (47).

The *pcy* gene in mice is orthologous to the *NPHP3* gene in humans; mutation in human *NPHP3* causes adolescent nephronophthisis (75). Phosphorylated S6K was slightly elevated at 4 weeks, moderately increased at 12 weeks, and markedly increased at 30 weeks of age, whereas phosphorylated ERK was uniformly increased at all ages (76). Administration of pellets releasing rapamycin from 20 to 30 weeks of age to male *pcy* mice at a rate of 3 mg/kg per d prevented further renal cystic enlargement and deterioration of renal function (76). However, treatment between 6 and 12 weeks of age was with-

Table 2. Summary of mTOR activation and sensitivity to mTOR inhibition in polycystic kidney rodent models

Rodent Model	Affected Protein	mTOR Activation in Kidneys?	Drug Treatment	Effective?	Reference
Han:SPRD rat (Cy/+ rat)	SamCystin (mutant protein)	Yes	SRL (0.2 mg/kg/d, IP) SRL (2 mg/kg/d, oral) EVL (3 mg/kg/d, oral)	Yes Yes Yes	Tao <i>et al.</i> (69) Wahl <i>et al.</i> (70) Wu <i>et al.</i> (72)
<i>Pkd1</i> mouse model	Polycystin-1 (conditional, knockout)	Yes	SRL (0.2 mg/kg/d, IP)	Yes (long term)	Zafar <i>et al.</i> (73)
<i>Pkd2</i> mouse model	Polycystin-2	Yes (liver)	SRL (2 mg/kg/d, oral)	Yes	Zhang <i>et al.</i> (71)
MAL-transgenic mouse	MAL/VIP17 (overexpression)	Yes (liver)	SRL (5 mg/kg/d, IP)	Yes	Shillingford <i>et al.</i> (80)
<i>orpk</i> -rescue mouse	Polaris (re-expression of Polaris in hypomorphic mutant)	Yes	SRL (1.5 mg/kg/d, IP) ND	Yes (liver) ND	Spirli <i>et al.</i> (81) Shillingford <i>et al.</i> (47)
<i>bpk</i> mouse	Bicaudal-C (mutant protein)	Yes	SRL (5 mg/kg/d, IP)	Yes	Shillingford <i>et al.</i> (47)
<i>pcy</i> mouse	Nephrocystin-3	Yes	SRL (5 mg/kg/d, IP) SRL (1.67 mg/kg/d, IP)	Yes Yes	Shillingford <i>et al.</i> (47) Gattone <i>et al.</i> (76)
Folliculin KO mouse	FLCN (kidney-specific, conditional KO)	Yes	SRL (3 mg/kg/d, oral) SRL (5 mg/kg/d, IP) SRL (2 mg/kg/d, IP)	Yes (late phase) Yes Yes	Reichardt (77) Baba <i>et al.</i> (46)

EVL, everolimus; IP, intraperitoneal; KO, knockout; ND, not determined; SRL, sirolimus.

out detectable effect, suggesting that mTOR activation may be less important at early stages of cystic disease in this animal model (76). Rapamycin was also protective in female *pcy* mice treated from 18 to 28 weeks of age (77).

Recently, rapamycin was tested in a cystic mouse model generated by a kidney-specific knockout of *BHD*, a gene that encodes FLCN (46). FLCN is the protein affected in BHD syndrome (78) and has been implicated in the regulation of the AMPK/mTOR pathway, although its exact function is unclear (79). These mice exhibit rapidly progressing PKD and die from renal failure by 3 weeks (46). Rapamycin treatment (2 mg/kg per d, intraperitoneally) reduced renal growth and nearly doubled the life span of the mice (46).

Finally, mTOR inhibitors have been recently tested in animal models orthologous to human ADPKD. Rapamycin treatment (5 mg/kg per d, intraperitoneally) was highly effective in a newly developed mouse model in which the *Pkd1* gene was inactivated in a mosaic fashion (80). Rapamycin treatment resulted in strong inhibition of renal cyst growth, partial reversal of the cystic phenotype in already enlarged kidneys, and preservation of renal function. Rapamycin (1.5 mg/kg per d, intraperitoneally) significantly reduced the liver/body weight ratio, liver cyst volume, and pericyclic microvascular density in a conditional *Pkd2* knockout mouse (81). In both studies, rapamycin reduced the rates of cell proliferation while enhancing the rates of apoptosis. These would suggest that mTOR inhibition may also be effective in human ADPKD.

Preclinical studies summarized in Table 2 indicate that mTOR inhibition may provide a potential clinical approach to slow the progression of PKD; however, several limitations to these studies should be considered. The doses of rapamycin or everolimus used in rodent studies exceed the dose commonly used for immunosuppression in patients. In rodents, high doses of mTOR inhibitors appear to be well tolerated with no adverse effects. Small reductions in body weight have been reported in some studies (69,71,73) but not others (76,82). Rapamycin at 3 mg/kg per d (intraperitoneally) was needed to achieve complete suppression of S6 phosphorylation in the brain of an epilepsy mouse model with conditional inactivation of the *TSC1* gene (82). To our knowledge, the dose of mTOR inhibitor required to adequately suppress mTOR in target organs, including PKD kidneys, in humans is unknown.

Retrospective Clinical Studies of mTOR in ADPKD

Some ADPKD patients who undergo renal transplantation receive rapamycin for immune suppression. This has led to the fortuitous circumstance in which some ADPKD patients with their native polycystic kidney still in place have been treated with rapamycin. It was reported in a small retrospective study that the total renal volumes decreased by approximately 25% during an average period of 2 years in transplanted ADPKD patients who were treated with rapamycin, whereas no significant change was found in the nonrapamycin control group (47). In a subsequent larger study, a similar trend was observed, but the difference from the control group did not achieve statistical significance (83). However, there was a significant

reduction in the total liver volumes, whereas the liver volumes increased in the control group (83). These results are encouraging because they suggest that the dose of rapamycin required for immunosuppression may be sufficient to suppress mTOR activity and the growth of liver and kidney cysts. An important caveat in these studies is that the kidneys of these patients represent highly cystic end-stage kidneys in which little, if any, normal renal tissue remains.

mTOR, Fibrosis Chronic Kidney Disease, and Animal Models of Noncystic Renal Disease

mTOR signaling is important in the regulation of intrinsic renal cell, T cell, and B cell proliferation and function. Therefore, it is not surprising that activation of mTOR has been implicated in the progression of chronic kidney disease (CKD), a common pathology of glomerulosclerosis and tubulointerstitial fibrosis initiated by many diverse causes of renal injury. mTOR inhibition can be beneficial or deleterious depending on the nature and severity of the underlying renal injury, timing of treatment in relation to the onset of disease, and dose of mTOR inhibitor.

Akt and/or mTOR are activated or play a role in nonimmunologic models of CKD, such as 5/6 nephrectomy (84,85), chronic ischemic nephropathy (86–88), unilateral ureteral obstruction (89,90), type I (streptozotocin-induced) (85,91–93) and type II (*db/db* mice and Zucker rat) (94,95) diabetic nephropathy, protein overload (96), and adriamycin- and puromycin-induced nephropathies. In all of these cases, administration of rapamycin inhibited the development and progression of the disease at least in part by inhibiting inflammation (87) and the expression of fibrosis-associated genes such as TGF- β (67,86,97). Of note is that whereas mTOR inhibition early after renal mass reduction caused further reduction in renal function (84), late treatment was protective (84). Similarly, mTOR inhibition delayed recovery from renal ischemia reperfusion injury in mice (98,99) and rats (64,100,101) and aggravated protein overload nephropathy (96), whereas it had a beneficial effect on chronic ischemic nephropathy induced by ischemia-reperfusion injury. These observations indicate that mTOR inhibition may interfere with adaptive increases in renal proliferation that are necessary for recovery from injury but inhibit potentially deleterious aspects of injury repair such as development of inflammation and fibrosis.

Interestingly, Rangan and Coombes (102) found that mTOR inhibition attenuates the renal enlargement in adriamycin nephropathy and the fibrosis without reducing proteinuria in rats, whereas Lui *et al.* (103) found that rapamycin given at the time adriamycin nephritis was induced or started 1 week after induction was effective in reducing the proteinuria, interstitial inflammation, and collagen expression. Everolimus pretreatment in puromycin aminonucleoside nephrosis similarly ameliorated the puromycin aminonucleoside-induced proteinuria and mononuclear leukocyte infiltration in mice (104). The attenuation of adriamycin- and puromycin-induced nephropathies contrasts with other reports that mTOR inhibitors impair

pathways essential for podocyte integrity and predispose to glomerular injury (see below) (105,106).

The mTOR pathway also affects the development and progression of immunologically mediated forms of CKD, such as membranous glomerulopathy (passive and active forms of Heymann nephritis) (65,107), mesangiocapillary anti-Thy-1 nephritis (108,109), lupus (105–107,110,111), and antiglomerular basement membrane GN (112). Whereas mTOR inhibitors usually exert beneficial effects consistent with their immunosuppressive and anti-inflammatory actions, they can be detrimental under certain conditions because of downregulation of vascular endothelial growth factor (VEGF). For example, administration of high-dose everolimus to rats early after “full-dose” anti-Thy-1 antiserum inhibits endothelial cell (EC) proliferation and increases apoptosis, crescent formation, glomerulosclerosis, and mortality, whereas low-dose everolimus or treatment of a less severe lesion (“reduced dose” anti-Thy-1 model) is relatively safe, and late treatment (after the acute proliferative phase) inhibits glomerular hypertrophy, glomerulosclerosis, proteinuria, and interstitial fibrosis and improves renal function (108,109). On the other hand, rapamycin significantly reduces B and T cell responses and protects from GN when administered early in the autologous phase of antiglomerular basement membrane GN, but it worsens GN by disturbing the EC/VEGF system in the kidney once disease is established (112).

Role of mTOR in Vascular Remodeling and Angiogenesis in ADPKD

The polycystins are strongly expressed in endothelial and vascular smooth muscle cells (VSMCs) (113–116). VSMCs from *Pkd1*^{+/-} or *Pkd2*^{+/-} mice exhibit an exaggerated contractile response to phenylephrine associated with lesser cytosolic calcium rise (117,118). ECs from *Pkd1* null mice lacking polycystin-1 in primary cilia cannot modulate calcium signaling and nitric oxide synthesis in response to fluid shear (119). Endothelium-dependent vasorelaxation is reduced in ADPKD (120). Therefore, it is not surprising that vascular pathology constitutes a prominent component of this disease. This includes renal (vascular remodeling, rarefaction, angiogenesis) and extrarenal [arterial aneurysms, dolichoectasias, and dissections (121), and possibly an increased risk for cerebral vasospasm (122) and atherosclerosis (123)] vascular pathologies.

The renal vasculature in ADPKD is characterized by small artery and arteriolar sclerosis, rarefaction, and angiogenesis at relatively early stages of the disease (121,124–128). These are not distinct, but are interrelated processes. Sustained vasoconstriction and increased blood pressure induce arterial/arteriolar hyperplasia and sclerosis, rarefaction, and focal ischemia (129). Ischemia through hypoxia-inducible transcription factors upregulates VEGF and other growth factors that stimulate angiogenesis (130). VEGF, normally expressed in tubular epithelia, is overexpressed in cyst epithelial cells (128,131). Inflammatory mediators in cyst fluids may contribute to the upregulation of VEGF (132), which in a paracrine fashion further stimulates angiogenesis and further cyst growth (131).

The PI3K/Akt/mTOR signaling pathway plays an important role in the vascular smooth muscle changes that occur in ADPKD. VSMC plasticity is important for pathologic responses such as intimal hyperplasia and atherosclerosis (133). These require dedifferentiation of VSMCs from a contractile to a proliferative, migratory, synthetic phenotype. Activation of mTOR effector S6K1, feedback inhibition of IRS-1, and inhibition of Akt2 mediate this phenotypic switch (134). Rapamycin blocks this pathway, promotes the differentiated contractile phenotype, inhibits VSMC migration and proliferation, and attenuates intimal hyperplasia. Consistent with these effects, inhibition of mTOR markedly reduces transplant vasculopathy in recipients of cardiac (118) and renal transplants (135) and the incidence of restenosis, although improving coronary artery physiology after rapamycin-eluting stents (136–139). Therefore, mTOR inhibitors have the potential of attenuating the renal vascular remodeling and possibly early development of atherosclerosis associated with ADPKD.

Both mTORC complexes and Akt signaling play a key role in angiogenesis (140–143). mTORC1 activates EC proliferation. mTORC2 directly phosphorylates Akt and promotes EC survival (13,144). Akt activates endothelial nitric oxide synthase by direct phosphorylation (145). Akt1, rather than Akt2, is required for acute permeability response to VEGF and angiogenesis in a hind-limb ischemia model (146). Contrary to VSMCs, where Akt is only partially inhibited after prolonged treatment with mTOR inhibitors, Akt is strongly inhibited in ECs after exposure to rapamycin for 24 hours (140). These effects on ECs and VSMCs may contribute to the increased risk of late coronary artery thrombosis and peri-stent coronary aneurysms with rapamycin-eluting stents (140,147–150).

Angiogenesis is required for tumor growth, and the antiangiogenic action of mTOR inhibitors is due at least in part to their antiangiogenic properties (151,152). Capillary sprouting and development of a rich vascular network around the cysts ensures that the proliferation of epithelial cells is matched by an adequate supply of blood and nutrients (127). Therefore, mTOR inhibition has the potential of preventing cyst expansion by its antiangiogenic effect (127). However, the results of antiangiogenic strategies targeting VEGF in PKD have been mixed. Treatment of Han:SPRD Cy/+ rats with ribozymes inhibiting mRNA expression of VEGF receptors 1 or 2 blunted cystogenesis and improved renal function (131). Administration of the VEGF receptor inhibitor SU-5416 to *Pkd2*^{WS25/-} mice was protective against the development of cystic disease in the liver, but not in the kidney (153). On the other hand, treatment of developing CD-1 mice with antibodies against VEGF receptor 2 promoted renal cyst growth (154).

Strategies targeting angiogenesis in ADPKD raise additional concerns. Apoptotic EC loss in peritubular capillaries is associated with interstitial fibrosis (155–157). By further inducing EC apoptosis, such strategies could potentially accelerate the development of interstitial fibrosis, a prominent feature in polycystic kidneys (124), and hasten the decline in kidney function. EC and VSMC apoptosis may be important in the pathogenesis of arterial aneurysms and dissections, well recognized extrarenal manifestations of ADPKD. However, to date, no association

between administration of mTOR inhibitors and aneurysmal rupture or arterial dissection has been reported. By their effects on nitric oxide production and VSMC contractility, mTOR inhibitors could enhance the development of hypertension or vasospastic complications. Although hypertension has been reported to be less common in mTOR than in calcineurin inhibitor-treated patients, a recent study has shown an equivalent development of hypertension in rats treated with mTOR or calcineurin inhibitors (158). Hypertension, proteinuria, and acute kidney injury are recognized adverse effects of anti-VEGF therapy (159).

Risk/Benefit Considerations for mTOR Inhibition Therapy: Lessons Learned from Organ Transplantation and Treatment of Glomerulopathies

mTOR inhibitors have gained a proper place in the present-day immunosuppressive armamentarium in renal transplantation (160–162). However, significant adverse events lead to discontinuation of mTOR inhibitors in between 7% and 37% of patients, with discontinuation reported to be directly related to exposure to sirolimus and tacrolimus (7.8% and 2.2%, respectively) (163,164). Nonrenal-related side effects are listed in Table 3. These, along with a mild to moderate nephrotoxic potential (see below), need to be kept in mind when considering the use of mTOR inhibitors for nontransplant and nonmalignant medical disorders such as ADPKD.

The mTOR inhibitor-induced dyslipidemia may result in part from a decrease in catabolism of apolipoprotein (apo)B₁₀₀-containing lipoproteins, possibly because of downregulation of LDL receptors (165,166). This hyperlipidemic effect should be weighed against the potential antiatherogenic effects of these drugs. Administration of everolimus to LDL receptor-deficient

(*LDLR*^{-/-}) mice markedly reduced the extent of atherosclerosis despite a 40% increase of plasma cholesterol (167). Although administration of rapamycin to transplant recipients increases cholesterol and triglyceride levels by 17 and 59 mg/dl (at a dose of 2 mg/d) or by 30 and 103 mg/dl (at a dose of 5 mg/d), respectively, compared with patients receiving placebo or azathioprine, and the Framingham risk model predicts that a 17-mg/dl elevation in cholesterol would increase the incidence of coronary heart disease by 1.5 new cases per 1000 persons per year and coronary heart disease death by 0.7 events per 1000 persons per year (168), no increase in the 4-year risk of cardiovascular events was detected in rapamycin-treated patients in a single-center study (169).

Of particular concern is their potential nephrotoxicity. In transplant patients, mTOR inhibitors cause delayed renal allograft function and increase the nephrotoxicity of calcineurin inhibitors. On the other hand, conversion from calcineurin to mTOR inhibitor-based immunosuppressive regimens offers the opportunity to improve renal function (170). The probability of benefit from this conversion diminishes with time from transplant, impairment of renal function, and severity of proteinuria (170,171). A large, multicenter, prospective, randomized, open-label rapamycin renal conversion trial (CONVERT) randomly assigned (2:1) 830 maintenance renal allograft recipients (stratified by baseline GFR; 20 to 40 *versus* >40 ml/min) to undergo conversion or to continue receiving calcineurin inhibitor-based therapy (172). Enrollment in the group with baseline GFR of 20 to 40 ml/min was discontinued because of a higher incidence of safety end points in the rapamycin conversion arm (16.7% *versus* 0%). In the patients with baseline GFR >40 ml/min and urine protein to creatinine ratio ≤0.11, a modest improvement in GFR was noted at 12 and 24 months. *De novo* proteinuria occurred as an unexpected finding after sirolimus conversion, and worsening proteinuria was associated with sclerotic glomeruli at baseline (172). A smaller study assessed outcomes by the magnitude of proteinuria at conversion (≤300, 301 to 3500, or >3500 mg/d). Increasing degree of proteinuria at baseline was associated with increased levels of creatinine 6 months later (173). Similar observations have been made in cardiac and pulmonary transplant patients (174,175).

The electrophoretic pattern, response to angiotensin-converting enzyme inhibitors, and demonstration of normal tubular endocytosis of albumin indicate that the proteinuria associated with the administration of mTOR inhibitors is of glomerular origin (176–178). Development of or increase in proteinuria after switching from a calcineurin to an mTOR inhibitor may in part be due to a renal hemodynamic effect (105). Nevertheless, a large body of evidence indicates that mTOR inhibitors are, at least in part, directly responsible. Development or increase in proteinuria has been observed in patients switched to rapamycin from an azathioprine-based regimen (179), in kidney transplant recipients treated *de novo* with mTOR inhibitors compared with control groups receiving calcineurin inhibitor-based (180–182) or mycophenolate-based (183) immunosuppressive regimens, and rarely in liver transplant recipients (184). In a few patients, proteinuria was in the nephrotic range and remitted after withdrawal of the drug (185). Prolonged rapamycin

Table 3. Nonrenal side effects of mTOR inhibitors (160,165,201)

Side Effect	Frequency
Hypertriglyceridemia	High
Hypercholesterolemia	High
Mucositis (mouth ulcers, diarrhea)	High
Folliculitis, acne, dermatitis	High
Anemia, leukopenia, thrombocytopenia	Moderate
Impaired wound healing	Moderate
Arthralgias	Moderate
Insulin resistance	Moderate
Liver enzyme elevations	Low
Decreased testosterone and spermatogenesis	Low
Eyelid or leg edema	Low
Angioedema	Rare
Lymphedema	Rare
Interstitial pneumonitis	Rare
Thrombotic microangiopathy	Rare

treatment of cultured human podocytes reduces the expression of total mTOR, mTORC1 activation, Rictor, mTORC2 formation, and Akt phosphorylation; downregulates nephrin, TRPC6, Nck, WT-1, and VEGF; and inhibits cell adhesion and motility (105,106).

There is limited information on the use of mTOR inhibitors in nontransplanted patients with underlying renal disease. Administration of rapamycin to patients with focal segmental glomerulosclerosis or proteinuric primary glomerulopathies has been associated with effects ranging from worsening of proteinuria and/or acute kidney injury (186,187) to partial or complete remission of the proteinuria in some patients (188). Proteinuria (1 to 7 g/d) or microalbuminuria developed in 3 and 5 of 62 type I diabetes mellitus patients, respectively, who underwent islet transplantation; in all patients, the proteinuria or microalbuminuria resolved after discontinuation of rapamycin (189). Proteinuria in ADPKD is usually low grade (<1 g/d) and associated with higher disease severity and worse prognosis (190–192). Currently, there is no information on whether administration of mTOR inhibitors to patients with ADPKD might increase proteinuria or negatively affect renal function, although it appeared to be safe in an animal model of PKD (76,193). Therefore, close monitoring of proteinuria and renal function is essential in clinical trials of mTOR inhibition in ADPKD, particularly in patients with more advanced stages of the disease.

Strategies for a Clinical Trial Design Using mTOR Inhibitors in ADPKD

Data from various longitudinal ADPKD cohort studies have demonstrated that cyst volume growth represents an exponential expansion process (194–196). These studies have also impressively shown that the GFR decline occurs only late in the disease, at a time when the kidney has already been irreversibly damaged by the relentlessly progressing cyst growth. The process of glomerular hyperfiltration might explain this dissociation between the steadily progressing cyst growth and the late GFR decline. The tardy decline of GFR is often accelerated, leading to ESRD within only a few years.

Therefore, the cyst volume growth rate represents a more suitable study end point than GFR decline, because the effect of a drug on cyst growth can be precisely monitored by repetitive magnetic resonance imaging or computed tomography scanning with subsequent volumetry of the kidneys and/or the cysts. GFR decline is a late phenomenon, and it might be difficult to obtain a therapeutic benefit with mTOR inhibitors at this later stage. This is also illustrated by another genetic disease, namely Fabry disease, which is a lysosomal storage disease for which it has been shown that late treatment with recombinant α -galactosidase enzyme replacement in proteinuric patients with impaired GFR has little or no effect (197). ADPKD and Fabry disease require establishment of treatment that is early and lifelong to be effective. Health authorities must be convinced to use cyst volume growth retardation as a meaningful clinical end point because it is likely that it will also retard or even prevent the occurrence of ESRD. It can also be expected that drugs that reduce cyst volume growth will have

an effect on other ADPKD-related morbidities, including delayed development of hypertension or less cyst bleeding.

ADPKD is a slowly progressing disease, requiring a long treatment time to detect meaningful effects of mTOR inhibitors on cyst volume growth retardation. Volume changes can reliably be detected in a short interval of 6 months (195); however, because approximately 10% to 20% of patients display volume regression within 6 months (because of the spontaneous rupture of cysts) (195), a much longer observation time is recommended. The dosage of the mTOR inhibitors must also be adapted to the specific side effect profile of these drugs. Mucositis, infections, hyperlipidemia, anemia, and thrombocytopenia are the most common, and the severity of these side effects depends on the dosage and the achieved trough levels. Therefore, for a lifelong treatment, it would be desirable to use a lower dosage than what is used for prevention of transplant rejection.

Currently, there is detailed information on the design of four ongoing clinical trials using mTOR inhibitors in patients with ADPKD (198,199). The data from these studies are summarized in Table 4. Several other additional small trials have been reported at scientific meetings, some of which have been published in abstract form (data not shown). A small pilot study of rapamycin (1 mg/d orally for 6 months) has recently reported promising results, but extraordinarily high rates of renal enlargement, particularly in the control group, were observed (200).

Three of the four trials use kidney (cyst) volume change as the primary end point. The patient numbers and dosing ranges are quite different in the four trials. The SUISSE ADPKD study enrolled 100 patients and is using rapamycin at 2 mg/d for 18 months. A larger German study enrolled 400 patients and is using everolimus for 2 years at a higher dose. The Cleveland Clinic and the Bergamo studies involve a smaller patient population with a dose-finding strategy.

Definitive data from these four clinical trials will be available in 2010. Certainly, if an important beneficial effect of mTOR inhibitors is found, more detailed dosing strategies targeting early, intermediate, and late stages of the disease need to be tested in additional trials. In the case that only a moderate positive effect is found, future trials could seek to establish whether combination therapy of mTOR inhibitors, which primarily target cell proliferation, with drugs targeting fluid secretion, would improve therapeutic results.

Currently, it is too early to recommend that patients with ADPKD start treatment with mTOR inhibitors. The results of the ongoing studies must be awaited, and patients must be informed accordingly.

Acknowledgments

This manuscript resulted from a meeting held in Montréal, Canada, October 11 to 12, 2008. The authors had total responsibility for the content and writing of the manuscript. The meeting was funded by Wyeth Pharmaceuticals [makers of Rapamune (sirolimus)], which was acquired by Pfizer, Inc., in October 2009. MediMedia Educational Group, LLC, provided support for the meeting. Each author, with the

Table 4. Currently active clinical trials using mTOR inhibitors in ADPKD

Study Name	Trial Number	Sponsor	Study Drug	Study Design	Treatment Duration (months)	Eligibility (age in years; GFR in ml/min/1.73 m ²)	Patient Number	Primary End Point	Completion Date
SUISSE ADPKD (202)	NCT00346918	University of Zürich, Zürich, Switzerland	SRL	Single-center, open-label, randomized	24	Age 18 to 40; GFR >70	100	Percent TKV change, MRI	June 2010
SIRENA study (203)	NCT00491517	Mario Negri Institute, Bergamo, Italy	SRL	Single-center, open-label, randomized, crossover	6	Age 18 to 80; GFR >40	16	TKV change, CT	December 2009
Sirolimus for ADPKD (204)	NCT00286156	The Cleveland Clinic, Cleveland, Ohio, United States	SRL	Single-center, open-label, randomized, dose comparison	12	Age ≥18; I: GFR ≥60, II: GFR: 25 to 59	30	Iothalamate GFR change (secondary end point, TKV/TLV, CT)	–
Everolimus in ADPKD (205)	NCT00414440	Novartis Pharmaceuticals, Basel, Switzerland	EVL	Multicenter, placebo-controlled, randomized	24	Age 18 to 65; GFR 30 to 89	400	TKV change, MRI	December 2009

CT, computed tomography; MRI, magnetic resonance imaging; TKV, total kidney volume; TLV, total liver volume.

exception of Drs. Qi Qian and Vicente E. Torres, received an honorarium from Wyeth Pharmaceuticals.

Disclosures

Dr. Vicente Torres has had research and is an investigator in clinical trials funded by Otsuka and Novartis Pharmaceuticals. Dr. Arlene Chapman has served as a consultant for Otsuka and Novartis Pharmaceuticals. Dr. Vincent Gattone has served as a consultant for Hoffmann–La Roche, has performed studies funded by Amgen and Genzyme, and has a patent licensed by Otsuka Pharmaceuticals. Dr. York Pei has served as a consultant to Novartis, Plexxikon, Roche, and Wyeth Pharmaceuticals. Dr. Qi Qian is principal investigator for an ADPKD study (Wyeth # 0468E6-4517). Dr. Darren P. Wallace is a consultant for Plexxikon, Inc. Dr. Rudolf P. Wüthrich has served as an advisory board member for Novartis and Wyeth Pharmaceuticals and has received grant support from Wyeth Pharmaceuticals for research in the field of ADPKD.

References

- Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. *Lancet* 369: 1287–1301, 2007
- Roach ES, Gomez MR, Northrup H: Tuberous sclerosis complex consensus conference: Revised clinical diagnostic criteria. *J Child Neurol* 13: 624–628, 1998
- European Chromosome 16 Tuberous Sclerosis Consortium: Identification and characterization of the tuberous sclerosis gene on chromosome 16. *Cell* 75: 1305–1315, 1993
- The European Polycystic Kidney Disease Consortium: The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. *Cell* 78: 725, 1994
- Venkatachalam K, Montell C: TRP channels. *Annu Rev Biochem* 76: 387–417, 2007
- Li Y, Corradetti MN, Inoki K, Guan KL: TSC2: Filling the GAP in the mTOR signaling pathway. *Trends Biochem Sci* 29: 32–38, 2004
- Brook-Carter PT, Peral B, Ward CJ, Thompson P, Hughes J, Maheshwar MM, Nellist M, Gamble V, Harris PC, Sampson JR: Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease—A contiguous gene syndrome. *Nat Genet* 8: 328–332, 1994
- Torres VE, Harris PC: Autosomal dominant polycystic kidney disease: The last 3 years. *Kidney Int* 76: 149–168, 2009
- Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism. *Cell* 124: 471–484, 2006
- Huang J, Manning BD: The TSC1-TSC2 complex: A molecular switchboard controlling cell growth. *Biochem J* 412: 179–190, 2008
- Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM: mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. *Cell* 110: 163–175, 2002
- Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM: Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. *Curr Biol* 14: 1296–1302, 2004
- Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM: Prolonged rapamycin

- mycin treatment inhibits mTORC2 assembly and Akt/PKB. *Mol Cell* 22: 159–168, 2006
14. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM: Phosphorylation and regulation of Akt/PKB by the Rictor-mTOR complex. *Science* 307: 1098–1101, 2005
 15. Saucedo LJ, Gao X, Chiarelli DA, Li L, Pan D, Edgar BA: Rheb promotes cell growth as a component of the insulin/TOR signaling network. *Nat Cell Biol* 5: 566–571, 2003
 16. Hsu YC, Chern JJ, Cai Y, Liu M, Choi KW: Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. *Nature* 445: 785–788, 2007
 17. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J: Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. *Curr Biol* 13: 1259–1268, 2003
 18. Ballif BA, Roux PP, Gerber SA, MacKeigan JP, Blenis J, Gygi SP: Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. *Proc Natl Acad Sci U S A* 102: 667–672, 2005
 19. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC: Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. *Mol Cell* 10: 151–162, 2002
 20. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J: Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. *Proc Natl Acad Sci U S A* 101: 13489–13494, 2004
 21. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP: Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. *Cell* 121: 179–193, 2005
 22. Inoki K, Zhu T, Guan KL: TSC2 mediates cellular energy response to control cell growth and survival. *Cell* 115: 577–590, 2003
 23. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO, Guan KL: TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. *Cell* 126: 955–968, 2006
 24. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WG Jr: Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. *Genes Dev* 18: 2893–2904, 2004
 25. Pearson RB, Dennis PB, Han JW, Williamson NA, Kozma SC, Wettenhall RE, Thomas G: The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. *EMBO J* 14: 5279–5287, 1995
 26. Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, Griffin JD, Kwiatkowski DJ: PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. *J Clin Invest* 117: 730–738, 2007
 27. Shah OJ, Wang Z, Hunter T: Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. *Curr Biol* 14: 1650–1656, 2004
 28. Shah OJ, Hunter T: Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis. *Mol Cell Biol* 26: 6425–6434, 2006
 29. Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC: Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. *Genes Dev* 19: 1773–1778, 2005
 30. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP: Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. *J Clin Invest* 118: 3065–3074, 2008
 31. Faivre S, Kroemer G, Raymond E: Current development of mTOR inhibitors as anticancer agents. *Nat Rev Drug Discov* 5: 671–688, 2006
 32. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J: Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. *Proc Natl Acad Sci U S A* 105: 17414–17419, 2008
 33. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di CS, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. *Cancer Res* 68: 8022–8030, 2008
 34. Molhoek KR, Brautigan DL, Slingluff CL Jr: Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor rapamycin. *J Transl Med* 3: 39, 2005
 35. Inoki K, Corradetti MN, Guan KL: Dysregulation of the TSC-mTOR pathway in human disease. *Nat Genet* 37: 19–24, 2005
 36. Rosner M, Hanneder M, Siegel N, Valli A, Fuchs C, Hengstschlager M: The mTOR pathway and its role in human genetic diseases. *Mutat Res* 659: 284–292, 2008
 37. Rosner M, Hengstschlager M: Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: Rapamycin triggers dephosphorylation and delocalization of the mTORC2 components Rictor and sin1. *Hum Mol Genet* 17: 2934–2948, 2008
 38. Hartman TR, Liu D, Zilfou JT, Robb V, Morrison T, Watanick T, Henske EP: The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway. *Hum Mol Genet* 18: 151–163, 2009
 39. Crino PB, Nathanson KL, Henske EP: The tuberous sclerosis complex. *N Engl J Med* 355: 1345–1356, 2006
 40. Kwiatkowski DJ, Manning BD: Tuberous sclerosis: A GAP at the crossroads of multiple signaling pathways. *Hum Mol Genet* 14: R251–R258, 2005
 41. Eng C: PTEN: One gene, many syndromes. *Hum Mutat* 22: 183–198, 2003
 42. Lachlan KL, Lucassen AM, Bunyan D, Temple IK: Cowden syndrome and Bannayan Riley Ruvulcaba syndrome represent one condition with variable expression and age-related penetrance: Results of a clinical study of PTEN mutation carriers. *J Med Genet* 44: 579–585, 2007
 43. McClatchey AI: Neurofibromatosis. *Annu Rev Pathol* 2: 191–216, 2007
 44. Corradetti MN, Inoki K, Bardeesy N, DePinho RA, Guan

- KL: Regulation of the TSC pathway by LKB1: Evidence of a molecular link between tuberous sclerosis complex and Peutz–Jeghers syndrome. *Genes Dev* 18: 1533–1538, 2004
45. Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, Iwamatsu A, Eposito D, Gillette WK, Hopkins RF III, Hartley JL, Furihata M, Oishi S, Zhen W, Burke TR Jr, Linehan WM, Schmidt LS, Zbar B: Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. *Proc Natl Acad Sci U S A* 103: 15552–15557, 2006
 46. Baba M, Furihata M, Hong SB, Tessarollo L, Haines DC, Southon E, Patel V, Igarashi P, Alvord WG, Leighty R, Yao M, Bernardo M, Ileva L, Choyke P, Warren MB, Zbar B, Linehan WM, Schmidt LS: Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. *J Natl Cancer Inst* 100: 140–154, 2008
 47. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. *Proc Natl Acad Sci U S A* 103: 5466–5471, 2006
 48. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. *N Engl J Med* 358: 140–151, 2008
 49. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP, Lamb RF: The TSC1–2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. *J Cell Biol* 166: 213–223, 2004
 50. The European Polycystic Kidney Disease Consortium: The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. *Cell* 77: 881–894, 1994
 51. Sandford R, Sgotto B, Burn T, Brenner S: The tuberin (TSC2), autosomal dominant polycystic kidney disease (PKD1), and somatostatin type V receptor (SSTR5) genes form a synteny group in the Fugu genome. *Genomics* 38: 84–86, 1996
 52. Bonnet CS, Aldred M, von Ruhland C, Harris R, Sandford R, Cheadle JP: Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis. *Hum Mol Genet* 18: 2166–2176, 2009
 53. Fischer DC, Jacoby U, Pape L, Ward CJ, Kuwertz-Broeking E, Renken C, Nizze H, Querfeld U, Rudolph B, Mueller-Wiefel DE, Bergmann C, Haffner D: Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD). *Nephrol Dial Transplant* 24: 1819–1827, 2009
 54. Cook JA, Oliver K, Mueller RF, Sampson J: A cross sectional study of renal involvement in tuberous sclerosis. *J Med Genet* 33: 480–484, 1996
 55. Weimbs T: Polycystic kidney disease and renal injury repair: Common pathways, fluid flow, and the function of polycystin-1. *Am J Physiol Renal Physiol* 293: F1423–F1432, 2007
 56. Weimbs T: Regulation of mTOR by polycystin-1: Is polycystic kidney disease a case of futile repair? *Cell Cycle* 5: 2425–2429, 2006
 57. Distefano G, Boca M, Rowe I, Wodarczyk C, Ma L, Piontek KB, Germino GG, Pandolfi PP, Boletta A: Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. *Mol Cell Biol* 29: 2359–2371, 2009
 58. Govindarajan B, Mizesko MC, Miller MS, Onda H, Nunnelley M, Casper K, Brat D, Cohen C, Arbiser JL: Tuberous sclerosis-associated neoplasms express activated p42/44 mitogen-activated protein (MAP) kinase, and inhibition of MAP kinase signaling results in decreased in vivo tumor growth. *Clin Cancer Res* 9: 3469–3475, 2003
 59. Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP: Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. *J Biol Chem* 279: 40419–40430, 2004
 60. Yamaguchi T, Hempson SJ, Reif GA, Hedge AM, Wallace DP: Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. *J Am Soc Nephrol* 17: 178–187, 2006
 61. Guan KL, Figueroa C, Brtva TR, Zhu T, Taylor J, Barber TD, Vojtek AB: Negative regulation of the serine/threonine kinase B-Raf by Akt. *J Biol Chem* 275: 27354–27359, 2000
 62. Wahl PR, Le Hir M, Vogetseder A, Arcaro A, Starke A, Waeckerle-Men Y, Serra AL, Wuthrich RP: Mitotic activation of Akt signaling pathway in Han:SPRD rats with polycystic kidney disease. *Nephrology (Carlton)* 12: 357–363, 2007
 63. DiJoseph JF, Sharma RN, Chang JY: The effect of rapamycin on kidney function in the Sprague–Dawley rat. *Transplantation* 53: 507–513, 1992
 64. Lieberthal W, Fuhro R, Andry CC, Rennke H, Abernathy VE, Koh JS, Valeri R, Levine JS: Rapamycin impairs recovery from acute renal failure: Role of cell-cycle arrest and apoptosis of tubular cells. *Am J Physiol Renal Physiol* 281: F693–F706, 2001
 65. Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, Lieberthal W: Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. *J Am Soc Nephrol* 16: 2063–2072, 2005
 66. Chen JK, Chen J, Neilson EG, Harris RC: Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. *J Am Soc Nephrol* 16: 1384–1391, 2005
 67. Wu MJ, Wen MC, Chiu YT, Chiou YY, Shu KH, Tang MJ: Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. *Kidney Int* 69: 2029–2036, 2006
 68. Brown JH, Bihoreau MT, Hoffmann S, Kranzlin B, Tychinskaya I, Obermuller N, Podlich D, Boehn SN, Kaisaki PJ, Megel N, Danoy P, Copley RR, Broxholme J, Witzgall R, Lathrop M, Gretz N, Gauguier D: Missense mutation in sterile alpha motif of novel protein SamCystin is associated with polycystic kidney disease in (Cy/+) rat. *J Am Soc Nephrol* 16: 3517–3526, 2005
 69. Tao Y, Kim J, Schrier RW, Edelstein CL: Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. *J Am Soc Nephrol* 16: 46–51, 2005
 70. Wahl PR, Serra AL, Le HM, Molle KD, Hall MN, Wuthrich

- RP: Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). *Nephrol Dial Transplant* 21: 598–604, 2006
71. Zhang T, Wang L, Xiong X, Mao Z, Wang L, Mei C: Mycophenolate mofetil *versus* rapamycin in Han:SPRD rats with polycystic kidney disease. *Biol Res* 42: 437–444, 2009
 72. Wu M, Wahl PR, Le HM, Wackerle-Men Y, Wuthrich RP, Serra AL: Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. *Kidney Blood Press Res* 30: 253–259, 2007
 73. Zafar I, Belibi FA, He Z, Edelstein CL: Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). *Nephrol Dial Transplant* 24: 2349–2353, 2009
 74. Brown NE, Murcia NS: Delayed cystogenesis and increased ciliogenesis associated with the re-expression of polaris in Tg737 mutant mice. *Kidney Int* 63: 1220–1229, 2003
 75. Olbrich H, Fliegauf M, Hoefele J, Kispert A, Otto E, Volz A, Wolf MT, Sasmaz G, Trauer U, Reinhardt R, Sudbrak R, Antignac C, Gretz N, Walz G, Schermer B, Benzing T, Hildebrandt F, Omran H: Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis. *Nat Genet* 34: 455–459, 2003
 76. Gattone VH, Sindors RM, Hornberger TA, Robling AG: Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis. *Kidney Int* 76: 178–182, 2009
 77. Reichardt W, Romaker D, Becker A, Buechert M, Walz G, von Elverfeldt D: Monitoring kidney and renal cyst volumes applying MR approaches on a rapamycin treated mouse model of ADPKD. *MAGMA* 22: 143–149, 2009
 78. Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, Turner ML, Duray P, Merino M, Choyke P, Pavlovich CP, Sharma N, Walther M, Munroe D, Hill R, Maher E, Greenberg C, Lerman MI, Linehan WM, Zbar B, Schmidt LS: Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. *Cancer Cell* 2: 157–164, 2002
 79. Hasumi H, Baba M, Hong SB, Hasumi Y, Huang Y, Yao M, Valera VA, Linehan WM, Schmidt LS: Identification and characterization of a novel folliculin-interacting protein FNIP2. *Gene* 415: 60–67, 2008
 80. Shillingford JM, Piontek KB, Germino GG, Weimbs T: Rapamycin ameliorates PKD resulting from conditional inactivation of *pkd1*. *J Am Soc Nephrol* 21: 489–497, 2010
 81. Spirli C, Okolicsanyi S, Fiorotto R, Fabris L, Cadamuro M, Lecchi S, Tian X, Somlo S, Strazzabosco M: Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice. *Hepatology* 51: 1–11, 2009
 82. Zeng LH, Xu L, Gutmann DH, Wong M: Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. *Ann Neurol* 63: 444–453, 2008
 83. Qian Q, Du H, King BF, Kumar S, Dean PG, Cosio FG, Torres VE: Sirolimus reduces polycystic liver volume in ADPKD patients. *J Am Soc Nephrol* 19: 631–638, 2008
 84. Vogelbacher R, Wittmann S, Braun A, Daniel C, Hugo C: The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. *Transplantation* 84: 1492–1499, 2007
 85. Sakaguchi M, Isono M, Isshiki K, Sugimoto T, Koya D, Kashiwagi A: Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. *Biochem Biophys Res Commun* 340: 296–301, 2006
 86. Jain S, Bicknell GR, Whiting PH, Nicholson ML: Rapamycin reduces expression of fibrosis-associated genes in an experimental model of renal ischaemia reperfusion injury. *Transplant Proc* 33: 556–558, 2001
 87. Yang B, Jain S, Pawluczuk IZ, Imtiaz S, Bowley L, Ashra SY, Nicholson ML: Inflammation and caspase activation in long-term renal ischemia/reperfusion injury and immunosuppression in rats. *Kidney Int* 68: 2050–2067, 2005
 88. Yang B, Jain S, Ashra SY, Furness PN, Nicholson ML: Apoptosis and caspase-3 in long-term renal ischemia/reperfusion injury in rats and divergent effects of immunosuppressants. *Transplantation* 81: 1442–1450, 2006
 89. Damiao MJ, Bertocchi AP, Monteiro RM, Goncalves GM, Cenedeze MA, Feitoza CQ, Marques GD, Giannocco G, Mazzali M, Teixeira VP, Dos Reis MA, Pacheco-Silva A, Camara NO: The effects of rapamycin in the progression of renal fibrosis. *Transplant Proc* 39: 457–459, 2007
 90. Schaefer L, Tsalastra W, Babelova A, Baliova M, Minnerup J, Sorokin L, Grone HJ, Reinhardt DP, Pfeilschifter J, Iozzo RV, Schaefer RM: Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and mammalian target of rapamycin. *Am J Pathol* 170: 301–315, 2007
 91. Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, Alperovich G, Rama I, Vidal A, Grinyo JM: Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. *J Am Soc Nephrol* 17: 1395–1404, 2006
 92. Wittmann S, Daniel C, Stief A, Vogelbacher R, Amann K, Hugo C: Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat. *Transplantation* 87: 1290–1299, 2009
 93. Yang Y, Wang J, Qin L, Shou Z, Zhao J, Wang H, Chen Y, Chen J: Rapamycin prevents early steps of the development of diabetic nephropathy in rats. *Am J Nephrol* 27: 495–502, 2007
 94. Zdychova J, Kazdova L, Pelikanova T, Lindsley JN, Anderson S, Komers R: Renal activity of Akt kinase in obese Zucker rats. *Exp Biol Med (Maywood)* 233: 1231–1241, 2008
 95. Sataranatarajan K, Mariappan MM, Lee MJ, Feliers D, Choudhury GG, Barnes JL, Kasinath BS: Regulation of elongation phase of mRNA translation in diabetic nephropathy: Amelioration by rapamycin. *Am J Pathol* 171: 1733–1742, 2007
 96. Coombes JD, Mreich E, Liddle C, Rangan GK: Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy. *Kidney Int* 68: 2599–2607, 2005
 97. Das F, Ghosh-Choudhury N, Mahimainathan L, Venkatesan B, Feliers D, Riley DJ, Kasinath BS, Choudhury GG: Raptor-Rictor axis in TGF β -induced protein synthesis. *Cell Signal* 20: 409–423, 2008
 98. Goncalves GM, Cenedeze MA, Feitoza CQ, de Paula CB, Marques GD, Pinheiro HS, de Paula Antunes Teixeira V, Antônia dos RM, Pacheco-Silva A, Câmara NO: The role of

- immunosuppressive drugs in aggravating renal ischemia and reperfusion injury. *Transplant Proc* 39: 417–420, 2007
99. Lui SL, Chan KW, Tsang R, Yung S, Lai KN, Chan TM: Effect of rapamycin on renal ischemia-reperfusion injury in mice. *Transpl Int* 19: 834–839, 2006
 100. Fuller TF, Freise CE, Serkova N, Niemann CU, Olson JL, Feng S: Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury. *Transplantation* 76: 1594–1599, 2003
 101. Lieberthal W, Fuhro R, Andry C, Patel V, Levine JS: Rapamycin delays but does not prevent recovery from acute renal failure: Role of acquired tubular resistance. *Transplantation* 82: 17–22, 2006
 102. Rangan GK, Coombes JD: Renoprotective effects of sirolimus in non-immune initiated focal segmental glomerulosclerosis. *Nephrol Dial Transplant* 22: 2175–2182, 2007
 103. Lui SL, Tsang R, Chan KW, Zhang F, Tam S, Yung S, Chan TM: Rapamycin attenuates the severity of murine adriamycin nephropathy. *Am J Nephrol* 29: 342–352, 2009
 104. Daniel C, Ziswiler R, Frey B, Pfister M, Marti HP: Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative. *Exp Nephrol* 8: 52–62, 2000
 105. Vollenbroeker B, George B, Wolfgart M, Saleem MA, Pavenstadt H, Weide T: mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. *Am J Physiol Renal Physiol* 296: F418–F426, 2009
 106. Letavernier E, Bruneval P, Vandermeersch S, Perez J, Mandet C, Belair MF, Haymann JP, Legendre C, Baud L: Sirolimus interacts with pathways essential for podocyte integrity. *Nephrol Dial Transplant* 24: 630–638, 2009
 107. Naumovic R, Jovovic D, Basta-Jovanovic G, Miloradovic Z, Mihailovic-Stanojevic N, Aleksic T, Jovanovic D: Effects of rapamycin on active Heymann nephritis. *Am J Nephrol* 27: 379–389, 2007
 108. Daniel C, Renders L, Amann K, Schulze-Lohoff E, Hauser IA, Hugo C: Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat. *Am J Transplant* 5: 2849–2861, 2005
 109. Wittmann S, Daniel C, Braun A, Vogelbacher R, Shimizu F, Kawachi H, Hugo C: The mTOR inhibitor everolimus attenuates the time course of chronic anti-Thy1 nephritis in the rat. *Nephron Exp Nephrol* 108: e45–e56, 2008
 110. Warner LM, Adams LM, Sehgal SN: Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. *Arthritis Rheum* 37: 289–297, 1994
 111. Ramos-Barrón A, Piñera-Haces C, Gómez-Alamillo C, Santiuste-Torcida I, Ruiz JC, Buelta-Carrillo L, Merino R, de Francisco AL, Arias M: Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment. *Lupus* 16: 775–781, 2007
 112. Hohegger K, Jansky GL, Soleiman A, Wolf AM, Tagwerker A, Seger C, Griesmacher A, Mayer G, Rosenkranz AR: Differential effects of rapamycin in anti-GBM glomerulonephritis. *J Am Soc Nephrol* 19: 1520–1529, 2008
 113. Griffin MD, Torres VE, Grande JP, Kumar R: Vascular expression of polycystin. *J Am Soc Nephrol* 8: 616–626, 1997
 114. Torres VE, Cai Y, Chen X, Wu GQ, Geng L, Cleghorn KA, Johnson CM, Somlo S: Vascular expression of polycystin-2. *J Am Soc Nephrol* 12: 1–9, 2001
 115. Ibraghimov-Beskrovnaya O, Dackowski WR, Foggensteiner L, Coleman N, Thiru S, Petry LR, Burn TC, Connors TD, Van RT, Bradley J, Qian F, Onuchic LF, Watnick TJ, Piontek K, Hakim RM, Landes GM, Germino GG, Sandford R, Klinger KW: Polycystin: *In vitro* synthesis, *in vivo* tissue expression, and subcellular localization identifies a large membrane-associated protein. *Proc Natl Acad Sci U S A* 94: 6397–6402, 1997
 116. Qian Q, Li M, Cai Y, Ward CJ, Somlo S, Harris PC, Torres VE: Analysis of the polycystins in aortic vascular smooth muscle cells. *J Am Soc Nephrol* 14: 2280–2287, 2003
 117. Morel N, Vandenberg G, Ahrabi AK, Caron N, Desjardins F, Balligand JL, Horie S, Devuyst O: PKD1 haploinsufficiency is associated with altered vascular reactivity and abnormal calcium signaling in the mouse aorta. *Pflugers Arch* 457: 845–856, 2009
 118. Raichlin E, Bae JH, Khalpey Z, Edwards BS, Kremers WK, Clavell AL, Rodeheffer RJ, Frantz RP, Rihal C, Lerman A, Kushwaha SS: Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. *Circulation* 116: 2726–2733, 2007
 119. Abou Alaiwi WA, Takahashi M, Mell BR, Jones TJ, Ratnam S, Kolb RJ, Nauli SM: Ciliary polycystin-2 is a mechanosensitive calcium channel involved in nitric oxide signaling cascades. *Circ Res* 104: 860–869, 2009
 120. Wang D, Iversen J, Wilcox CS, Strandgaard S: Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. *Kidney Int* 64: 1381–1388, 2003
 121. Ritter SA, Baehr G: The arterial supply of the congenital polycystic kidney and its relation to the clinical picture. *J Urol* 21: 583–592, 1929
 122. Chapman AB, Rubinstein D, Hughes R, Stears JC, Earnest MP, Johnson AM, Gabow PA, Kaehny WD: Intracranial aneurysms in autosomal dominant polycystic kidney disease. *N Engl J Med* 327: 916–920, 1992
 123. Turkmen K, Oflaz H, Uslu B, Cimen AO, Elitok A, Kasikcioglu E, Alisir S, Tufan F, Namli S, Uysal M, Ecder T: Coronary flow velocity reserve and carotid intima media thickness in patients with autosomal dominant polycystic kidney disease: From impaired tubules to impaired carotid and coronary arteries. *Clin J Am Soc Nephrol* 3: 986–991, 2008
 124. Zeier M, Fehrenbach P, Geberth S, Mohring K, Waldherr R, Ritz E: Renal histology in polycystic kidney disease with incipient and advanced renal failure. *Kidney Int* 42: 1259–1265, 1992
 125. Schacht FW: Hypertension in cases of polycystic kidney. *Arch Intern Med* 47: 500–509, 1931
 126. Ettinger A, Kahn PC, Wise HM Jr: The importance of selective renal angiography in the diagnosis of polycystic disease. *J Urol* 102: 156–161, 1969
 127. Wei W, Popov V, Walocha JA, Wen J, Bello-Reuss E: Evidence of angiogenesis and microvascular regression in autosomal-dominant polycystic kidney disease kidneys: A corrosion cast study. *Kidney Int* 70: 1261–1268, 2006
 128. Bello-Reuss E, Holubec K, Rajaraman S: Angiogenesis in autosomal-dominant polycystic kidney disease. *Kidney Int* 60: 37–45, 2001
 129. Martinez-Lemus LA, Hill MA, Meininger GA: The plastic nature of the vascular wall: a continuum of remodeling

- events contributing to control of arteriolar diameter and structure. *Physiology (Bethesda)* 24: 45–57, 2009
130. Humar R, Kiefer FN, Berns H, Resink TJ, Bategay EJ: Hypoxia enhances vascular cell proliferation and angiogenesis *in vitro* via rapamycin (mTOR)-dependent signaling. *FASEB J* 16: 771–780, 2002
 131. Tao Y, Kim J, Yin Y, Zafar I, Falk S, He Z, Faubel S, Schrier RW, Edelstein CL: VEGF receptor inhibition slows the progression of polycystic kidney disease. *Kidney Int* 72: 1358–1366, 2007
 132. Angelo LS, Kurzrock R: Vascular endothelial growth factor and its relationship to inflammatory mediators. *Clin Cancer Res* 13: 2825–2830, 2007
 133. Rzuclido EM, Martin KA, Powell RJ: Regulation of vascular smooth muscle cell differentiation. *J Vasc Surg* 45[Suppl A]: A25–A32, 2007
 134. Martin KA, Merenick BL, Ding M, Fetalvero KM, Rzuclido EM, Kozul CD, Brown DJ, Chiu HY, Shyu M, Drapeau BL, Wagner RJ, Powell RJ: Rapamycin promotes vascular smooth muscle cell differentiation through insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt2 feedback signaling. *J Biol Chem* 282: 36112–36120, 2007
 135. Jindra PT, Jin YP, Rozengurt E, Reed EF: HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. *J Immunol* 180: 2357–2366, 2008
 136. Mourani PM, Garl PJ, Wenzlau JM, Carpenter TC, Stenmark KR, Weiser-Evans MC: Unique, highly proliferative growth phenotype expressed by embryonic and neointimal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN. *Circulation* 109: 1299–1306, 2004
 137. Tang Z, Wang Y, Fan Y, Zhu Y, Chien S, Wang N: Suppression of c-Cbl tyrosine phosphorylation inhibits neointimal formation in balloon-injured rat arteries. *Circulation* 118: 764–772, 2008
 138. Sousa JE, Costa MA, Abizaid A, Feres F, Seixas AC, Tanajura LF, Mattos LA, Falotico R, Jaeger J, Popma JJ, Serruys PW, Sousa AG: Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. *Circulation* 111: 2326–2329, 2005
 139. Sinha SS, Pham MX, Vagelos RH, Perloth MG, Hunt SA, Lee DP, Valentine HA, Yeung AC, Fearon WF: Effect of rapamycin therapy on coronary artery physiology early after cardiac transplantation. *Am Heart J* 155: 889.e1–e6, 2008
 140. Barilli A, Visigalli R, Sala R, Gazzola GC, Parolari A, Tremoli E, Bonomini S, Simon A, Closs EI, Dall'Asta V, Bussolati O: In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function. *Cardiovasc Res* 78: 563–571, 2008
 141. Dada S, Demartines N, Dormond O: mTORC2 regulates PGE2-mediated endothelial cell survival and migration. *Biochem Biophys Res Commun* 372: 875–879, 2008
 142. Li W, Petrimpol M, Molle KD, Hall MN, Bategay EJ, Humar R: Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2. *Circ Res* 100: 79–87, 2007
 143. Xue Q, Nagy JA, Manseau EJ, Phung TL, Dvorak HF, Benjamin LE: Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase. *Arterioscler Thromb Vasc Biol* 29: 1172–1178, 2009
 144. Dormond O, Madsen JC, Briscoe DM: The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. *J Biol Chem* 282: 23679–23686, 2007
 145. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC: Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. *Nature* 399: 597–601, 1999
 146. Ackah E, Yu J, Zoellner S, Iwakiri Y, Skurk C, Shibata R, Ouchi N, Easton RM, Galasso G, Birnbaum MJ, Walsh K, Sessa WC: Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. *J Clin Invest* 115: 2119–2127, 2005
 147. Bavry AA, Chiu JH, Jefferson BK, Karha J, Bhatt DL, Ellis SG, Whitlow PL: Development of coronary aneurysm after drug-eluting stent implantation. *Ann Intern Med* 146: 230–232, 2007
 148. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. *JAMA* 293: 2126–2130, 2005
 149. Lee SE, John SH, Lim JH, Rhew JY: Very late stent thrombosis associated with multiple stent fractures and persistent aneurysm formation after sirolimus-eluting stent implantation. *Circ J* 72: 1201–1204, 2008
 150. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, Mintz GS, Nagata S: Incomplete neointimal coverage of sirolimus-eluting stents: Angioscopic findings. *J Am Coll Cardiol* 47: 2108–2111, 2006
 151. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. *Nat Med* 8: 128–135, 2002
 152. Fujishita T, Aoki K, Lane HA, Aoki M, Taketo MM: Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. *Proc Natl Acad Sci U S A* 105: 13544–13549, 2008
 153. Amura CR, Brodsky KS, Groff R, Gattone VH, Voelkel NF, Doctor RB: VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/–) mice. *Am J Physiol Cell Physiol* 293: C419–C428, 2007
 154. Grath-Morrow S, Cho C, Molls R, Burne-Taney M, Haas M, Hicklin DJ, Tuder R, Rabb H: VEGF receptor 2 blockade leads to renal cyst formation in mice. *Kidney Int* 69: 1741–1748, 2006
 155. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ: Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. *J Am Soc Nephrol* 12: 1448–1457, 2001
 156. Kang DH, Johnson RJ: Vascular endothelial growth factor: A new player in the pathogenesis of renal fibrosis. *Curr Opin Nephrol Hypertens* 12: 43–49, 2003
 157. Fine LG, Norman JT: Chronic hypoxia as a mechanism of progression of chronic kidney diseases: From hypothesis to novel therapeutics. *Kidney Int* 74: 867–872, 2008
 158. Reis F, Parada B, Teixeira de Lemos, Garrido P, Dias A, Piloto N, Baptista S, Sereno J, Eufrásio P, Costa E, Rocha-Pereira P, Santos-Silva A, Figueiredo A, Mota A, Teixeira F:

- Hypertension induced by immunosuppressive drugs: A comparative analysis between sirolimus and cyclosporine. *Transplant Proc* 41: 868–873, 2009
159. Gurevich F, Perazella MA: Renal effects of anti-angiogenesis therapy: Update for the internist. *Am J Med* 122: 322–328, 2009
 160. Augustine JJ, Bodziak KA, Hricik DE: Use of sirolimus in solid organ transplantation. *Drugs* 67: 369–391, 2007
 161. Dunn C, Croom KF: Everolimus: A review of its use in renal and cardiac transplantation. *Drugs* 66: 547–570, 2006
 162. Flechner SM: Sirolimus in kidney transplantation indications and practical guidelines: *De novo* sirolimus-based therapy without calcineurin inhibitors. *Transplantation* 87[Suppl 8]: S1–S6, 2009
 163. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, Margreiter R, Hugo C, Grinyo JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF: Reduced exposure to calcineurin inhibitors in renal transplantation. *N Engl J Med* 357: 2562–2575, 2007
 164. Larson TS, Dean PG, Stegall MD, Griffin MD, Textor SC, Schwab TR, Gloor JM, Cosio FG, Lund WJ, Kremers WK, Nyberg SL, Ishitani MB, Prieto M, Velosa JA: Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. *Am J Transplant* 6: 514–522, 2006
 165. Kasiske BL, de Mattos A, Flechner SM, Gallon L, Meier-Kriesche HU, Weir MR, Wilkinson A: Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. *Am J Transplant* 8: 1384–1392, 2008
 166. Hoogeveen RC, Ballantyne CM, Pownall HJ, Opekun AR, Hachey DL, Jaffe JS, Oppermann S, Kahan BD, Morrisett JD: Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients. *Transplantation* 72: 1244–1250, 2001
 167. Mueller MA, Beutner F, Teupser D, Ceglarek U, Thiery J: Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR^{-/-} mice despite severe hypercholesterolemia. *Atherosclerosis* 198: 39–48, 2008
 168. Blum CB: Effects of sirolimus on lipids in renal allograft recipients: An analysis using the Framingham risk model. *Am J Transplant* 2: 551–559, 2002
 169. Chueh S-C, Kahan BD: Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: Incidence, risk factors, progression, and prognosis. *Transplantation* 76: 375–382, 2003
 170. Mulay AV, Cockfield S, Stryker R, Fergusson D, Knoll GA: Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: A systematic review of the evidence. *Transplantation* 82: 1153–1162, 2006
 171. Wali RK, Weir MR: Chronic allograft dysfunction: Can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function? *Curr Opin Organ Transplant* 13: 614–621, 2008
 172. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF; for the Sirolimus CONVERT Trial Study Group: Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. *Transplantation* 87: 233–242, 2009
 173. Ruiz JC, Campistol JM, Sanchez-Fructuoso A, Rivera C, Oliver J, Ramos D, Campos B, Arias M, Diekmann F: Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. *Nephrol Dial Transplant* 21: 3252–3257, 2006
 174. Aliabadi D, Kammerstatter G, Seebacher G, Rodler S, Wolner E, Grimm M, Pohanka E, Zuckermann A: Development of proteinuria after switch to sirolimus based immunosuppression in long term cardiac transplant patients. *Am J Transplant* 8: 854–861, 2008
 175. Stephany BR, Boumitri M, Budev M, Alao B, Poggio ED: Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease. *J Heart Lung Transplant* 28: 564–571, 2009
 176. Mreich E, Coombes JD, Rangan GK: Sirolimus does not reduce receptor-mediated endocytosis of albumin in proximal tubule cells. *Transplantation* 83: 105–107, 2007
 177. Letavernier E, Pe'raldi M-N, Pariente A, Morelon E, Legendre C: Proteinuria following a switch from calcineurin inhibitors to sirolimus. *Transplantation* 80: 1198–1203, 2005
 178. Letavernier E, Legendre C: mTOR inhibitors-induced proteinuria: Mechanisms, significance, and management. *Transplant Rev (Orlando)* 22: 125–130, 2008
 179. van den Akker JM, Wetzels JF, Hoitsma AJ: Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. *Kidney Int* 70: 1355–1357, 2006
 180. Lebranchu Y, Etienne I, Topance O, Westeel PF, Legendre C, de Ligny BH, Le Meur Y, Moulin B, Touchard G, Deteix P, Villemain F, Le Pogamp P, Noel C, Idier I: Preliminary results of a randomized trial comparing sirolimus (SRL) vs cyclosporine (CsA) in 150 transplant recipients receiving a cadaveric renal graft. *Transplantation* 78: 463, 2004
 181. Stephany BR, Augustine JJ, Krishnamurthi V, Goldfarb DA, Flechner SM, Braun WE, Hricik DE, Dennis VW, Poggio ED: Differences in proteinuria and graft function in *de novo* sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. *Transplantation* 82: 368–374, 2006
 182. Buchler M, Caillard S, Barbier S, Thervet E, Toupance O, Mazouz H, Hurault de Ligny B, Le Meur Y, Thierry A, Villemain F, Heng AE, Moulin B, Morin MP, Noel C, Lebranchu Y: Sirolimus *versus* cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. *Am J Transplant* 7: 2522–2531, 2007
 183. Diekmann F, Gutierrez-Dalmau A, Lopez S, Cofan F, Esforzado N, Ricart MJ, Rossich E, Saval N, Torregrosa JV, Oppenheimer F, Campistol JM: Influence of sirolimus on proteinuria in *de novo* kidney transplantation with expanded criteria donors: Comparison of two CNI-free protocols. *Nephrol Dial Transplant* 22: 2316–2321, 2007
 184. Neau-Cransac M, Moreau K, Deminiere C, Merville P, Saric J: Decrease in sirolimus-induced proteinuria after switch to everolimus in a liver transplant recipient with diabetic nephropathy. *Transpl Int* 22: 586–587, 2009
 185. Letavernier E, Bruneval P, Mandet C, Van Huyen JP, Peraldi MN, Helal I, Noel LH, Legendre C: High sirolimus levels may induce focal segmental glomerulosclerosis *de novo*. *Clin J Am Soc Nephrol* 2: 326–333, 2007
 186. Fervenza FC, Fitzpatrick PM, Mertz J, Erickson SB, Liggett

- S, Popham S, Wochos DN, Synhavsky A, Hippler S, Larson TS, Bagniewski SM, Velosa JA: Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. *Nephrol Dial Transplant* 19: 1288–1292, 2004
187. Rangan GK: Sirolimus-associated proteinuria and renal dysfunction. *Drug Saf* 29: 1153–1161, 2006
188. Tumlin JA, Miller D, Near M, Selvaraj S, Hennigar R, Guasch A: A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. *Clin J Am Soc Nephrol* 1: 109–116, 2006
189. Senior PA, Paty BW, Cockfield SM, Ryan EA, Shapiro AM: Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. *Am J Transplant* 5: 2318–2323, 2005
190. Chapman AB, Johnson AM, Gabow PA, Schrier RW: Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 5: 1349–1354, 1994
191. Sharp C, Johnson A, Gabow P: Factors relating to urinary protein excretion in children with autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 9: 1908–1914, 1998
192. Torres VE: Hypertension, proteinuria, and progression of autosomal dominant polycystic kidney disease: Where do we go from here? *Am J Kidney Dis* 35: 547–550, 2000
193. Serra AL, Kistler AD, Poster D, Krauer F, Senn O, Raina S, Pavik I, Rentsch K, Regeniter A, Weishaupt D, Wüthrich RP: Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease. *Nephrol Dial Transplant* 24: 3334–3342, 2009
194. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr., Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP: Volume progression in polycystic kidney disease. *N Engl J Med* 354: 2122–2130, 2006
195. Kistler AD, Poster D, Krauer F, Weishaupt D, Raina S, Senn O, Binet I, Spanaus K, Wüthrich RP, Serra AL: Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. *Kidney Int* 75: 235–241, 2009
196. Franz KA, Reubi FC: Rate of functional deterioration in polycystic kidney disease. *Kidney Int* 23: 526–529, 1983
197. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ: Agalsidase-beta therapy for advanced Fabry disease: A randomized trial. *Ann Intern Med* 146: 77–86, 2007
198. Serra AL, Kistler AD, Poster D, Strucker M, Wüthrich RP, Weishaupt D, Tschirch F: Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSSE ADPKD study. *BMC Nephrol* 8: 13, 2007
199. Walz G: Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): Is there light at the end of the tunnel? *Nephrol Dial Transplant* 21: 1752–1757, 2006
200. Soliman AR, Ismail E, Zamil S, Lotfy A: Sirolimus therapy for patients with adult polycystic kidney disease: A pilot study. *Transplant Proc* 41: 3639–3641, 2009
201. Stallone G, Infante B, Grandaliano G, Gesualdo L: Management of side effects of sirolimus therapy. *Transplantation* 87[Suppl 8]: S23–S26, 2009
202. Sirolimus (Rapamune[®]) for autosomal dominant polycystic kidney disease (ADPKD), Bethesda, MD, National Institutes of Health, 2008. Available online at <http://clinicaltrials.gov/ct2/show/NCT00346918>. Accessed December 17, 2008
203. Sirolimus treatment in patients with autosomal dominant polycystic kidney disease: Renal efficacy and safety (SI-RENA), Bethesda, MD, National Institutes of Health, 2007. Available online at <http://clinicaltrials.gov/ct2/show/NCT00491517>. Accessed December 18, 2009
204. Pilot study of rapamycin as treatment for autosomal dominant polycystic kidney disease (ADPKD), Bethesda, MD, National Institutes of Health, 2006. Available online at <http://clinicaltrials.gov/ct2/show/NCT00286156>. Accessed November 18, 2009
205. Efficacy, safety and tolerability of everolimus in preventing end-stage renal disease in patients with autosomal dominant polycystic kidney disease, Bethesda, MD, National Institutes of Health, 2008. Available online at <http://clinicaltrials.gov/ct2/show/NCT00414440?term=NCT00414440>. Accessed November 18, 2009